

Date: 7<sup>th</sup> October, 2017

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Tower,  
Dalal Street, Fort  
Mumbai - 400 001

Dear Sir/Madam,

**Sub: Statement regarding investor complaints as per Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30<sup>th</sup> September, 2017**

With reference to the captioned subject, we enclose herewith Statement regarding investor complaints as per Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30<sup>th</sup> September, 2017.

We request you to kindly take the same on record.

Thanking you,

Yours Faithfully,  
**For Alembic Pharmaceuticals Limited**

*A. K. Desai*

**Ajay Kumar Desai**  
**Sr. VP-Finance & Company Secretary**

Encl.: A/a

Date: 7<sup>th</sup> October, 2017

Statement regarding Investor Complaints as per Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30<sup>th</sup> September, 2017 is as under:

No. of investor complaints pending at the beginning of the quarter	Nil
No. of investor complaints received during the quarter	2
No. of investor complaints disposed of during the quarter	2
No. of investor complaints unresolved at the end of the quarter	Nil

For Alembic Pharmaceuticals Limited

  
Ajay Kumar Desai  
Sr. VP - Finance & Company Secretary